{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:07:01Z","timestamp":1794002821035,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pure red cell aplasia (PRCA) is a relevant complication after ABO-mismatched allogeneic hematopoietic cell transplantation (HCT). No standard treatment exists, and practice is heterogenous. In this study, we took advantage of an international collaboration to describe characteristics and outcomes of patients receiving daratumumab for PRCA following first allogeneic HCT. We identified 45 patients meeting these criteria (median patient age, 56 years). The median time from HCT to PRCA was 55 days (IQR, 36\u2013116) and all patients were transfusion-dependent at time of daratumumab start. Daratumumab was first-line treatment in 16 patients (36%), most patients (67%) received daratumumab intravenously, and median time from PRCA diagnosis and daratumumab start was 88 days (IQR, 59\u2013219). Incidence of transfusion independence was 69% (95% confidence interval [CI], 52\u201380%) at 6 months and 80% (95% CI, 62\u201390%) at 12 months. Incidences of hemoglobin and reticulocyte recoveries were respectively 56 and 78% at 6 months and 65 and 83% at 12 months. Survival at 12 months was 81%, and of 8 deaths, 7 were GVHD- or infection-related. One death was associated with hemolytic anemia. This is the first international and largest study on the use of daratumumab for PRCA after allogeneic HCT, showing high response rates superior to that reported for other treatments. Seven incidents of severe adverse events (mostly infections) underscore the need for close monitoring, proactive management, and comparative studies to determine the role for daratumumab for PRCA. Last, based on these data and a comprehensive literature review, we provide practical consideration for modern PRCA treatment.<\/jats:p>","DOI":"10.1038\/s41408-025-01315-8","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:35:56Z","timestamp":1749036956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moniek de","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Peczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9739-0816","authenticated-orcid":false,"given":"William","family":"Boreland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annoek E. C.","family":"Broers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4136","authenticated-orcid":false,"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Esquirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Errico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-5332","authenticated-orcid":false,"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Parma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Di Chio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-5596","authenticated-orcid":false,"given":"Lucia","family":"L\u00f3pez Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rif\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-220X","authenticated-orcid":false,"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"1315_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41409-020-01124-6","volume":"56","author":"J Marco-Ayala","year":"2021","unstructured":"Marco-Ayala J, Gomez-Segui I, Sanz G, Solves P. Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question. Bone Marrow Transpl. 2021;56:769\u201378. https:\/\/doi.org\/10.1038\/s41409-020-01124-6.","journal-title":"Bone Marrow Transpl"},{"key":"1315_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/asheducation-2016.1.51","volume":"2016","author":"RT Means Jr","year":"2016","unstructured":"Means RT Jr. Pure red cell aplasia. Hematol Am Soc Hematol Educ Program. 2016;2016:51\u201356. https:\/\/doi.org\/10.1182\/asheducation-2016.1.51.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1315_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/sj.bmt.1701012","volume":"20","author":"A Santamaria","year":"1997","unstructured":"Santamaria A, Sureda A, Martino R, Domingo-Albos A, Muniz-Diaz E, Brunet S. Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transpl. 1997;20:1105\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1701012.","journal-title":"Bone Marrow Transpl"},{"key":"1315_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.0041-1132.2005.00445.x","volume":"45","author":"F Sora","year":"2005","unstructured":"Sora F, De Matteis S, Piccirillo N, Chiusolo P, Laurenti L, Putzulu R, et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion. 2005;45:643\u20135. https:\/\/doi.org\/10.1111\/j.0041-1132.2005.00445.x.","journal-title":"Transfusion"},{"key":"1315_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.amjms.2023.06.009","volume":"366","author":"RT Means Jr","year":"2023","unstructured":"Means RT Jr. Pure red cell aplasia: the second hundred years. Am J Med Sci. 2023;366:160\u20136. https:\/\/doi.org\/10.1016\/j.amjms.2023.06.009.","journal-title":"Am J Med Sci"},{"key":"1315_CR6","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1003032.","journal-title":"J Immunol"},{"key":"1315_CR7","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","volume":"379","author":"CI Chapuy","year":"2018","unstructured":"Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 2018;379:1846\u201350.","journal-title":"N Engl J Med"},{"key":"1315_CR8","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41409-019-0664-4","volume":"55","author":"C Rautenberg","year":"2020","unstructured":"Rautenberg C, Kaivers J, Germing U, Haas R, Ackerstaff S, Hoffmann T, et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. Bone Marrow Transpl. 2020;55:1191\u20133. https:\/\/doi.org\/10.1038\/s41409-019-0664-4.","journal-title":"Bone Marrow Transpl"},{"key":"1315_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2022.100314","volume":"17","author":"T Asawapanumas","year":"2022","unstructured":"Asawapanumas T, Chanswangphuwana C, Watanaboonyongcharoen P, Rojnuckarin P, Bunworasate U. Daratumumab as a frontline immunosuppression for pure red cell aplasia after major ABO-mismatched allogeneic hematopoietic stem cell transplantation. Leuk Res Rep. 2022;17:100314. https:\/\/doi.org\/10.1016\/j.lrr.2022.100314.","journal-title":"Leuk Res Rep"},{"key":"1315_CR10","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3324\/haematol.2022.281398","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Bleeker J, Lynch D, Olteanu H, Letendre L, Tefferi A. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. Haematologica. 2022;107:2523\u20136. https:\/\/doi.org\/10.3324\/haematol.2022.281398.","journal-title":"Haematologica"},{"key":"1315_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41409-021-01507-3","volume":"57","author":"R Martino","year":"2022","unstructured":"Martino R, Garcia-Cadenas I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. Bone Marrow Transpl. 2022;57:282\u20135. https:\/\/doi.org\/10.1038\/s41409-021-01507-3.","journal-title":"Bone Marrow Transpl"},{"key":"1315_CR12","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/bloodadvances.2023011190","volume":"8","author":"F Weverling","year":"2024","unstructured":"Weverling F, Roeven M, Nijssen C, Broers AEC, Dovern E, van Rhenen A, et al. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data. Blood Adv. 2024;8:1683\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2023011190.","journal-title":"Blood Adv"},{"key":"1315_CR13","doi-asserted-by":"publisher","first-page":"E216","DOI":"10.1002\/ajh.25515","volume":"94","author":"S Bathini","year":"2019","unstructured":"Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol. 2019;94:E216\u2013E219. https:\/\/doi.org\/10.1002\/ajh.25515.","journal-title":"Am J Hematol"},{"key":"1315_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/bjh.17463","volume":"193","author":"T Longval","year":"2021","unstructured":"Longval T, Galimard JE, Lepretre AC, Suarez F, Amiranoff D, Cazaux M, et al. Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol. 2021;193:814\u201326. https:\/\/doi.org\/10.1111\/bjh.17463.","journal-title":"Br J Haematol"},{"key":"1315_CR15","doi-asserted-by":"publisher","unstructured":"Melchert M, List AF. Management of RBC-transfusion dependence. Hematol Am Soc Hematol Educ Program. 2007:398\u2013404. https:\/\/doi.org\/10.1182\/asheducation-2007.1.398","DOI":"10.1182\/asheducation-2007.1.398"},{"key":"1315_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41409-024-02202-9","volume":"59","author":"T Longval","year":"2024","unstructured":"Longval T, Lepretre AC, Ravinet A, Fayard A, Forcade E, Coman T, et al. Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC. Bone Marrow Transpl. 2024;59:893\u20135. https:\/\/doi.org\/10.1038\/s41409-024-02202-9.","journal-title":"Bone Marrow Transpl"},{"key":"1315_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113395","volume":"153","author":"W Li","year":"2022","unstructured":"Li W, Liang L, Liao Q, Li Y, Zhou Y. CD38: an important regulator of T cell function. Biomed Pharmacother. 2022;153:113395 https:\/\/doi.org\/10.1016\/j.biopha.2022.113395.","journal-title":"Biomed Pharmacother"},{"key":"1315_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1159\/000515257","volume":"144","author":"I Henig","year":"2021","unstructured":"Henig I, Yehudai-Ofir D, Zohar Y, Zuckerman T. Pure red cell aplasia following ABO-mismatched allogeneic hematopoietic stem cell transplantation: resolution with daratumumab treatment. Acta Haematol. 2021;144:683\u20137. https:\/\/doi.org\/10.1159\/000515257.","journal-title":"Acta Haematol"},{"key":"1315_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.14740\/jh1195","volume":"12","author":"C Wu","year":"2023","unstructured":"Wu C, Manchen P, Edelman A, Husnain M, Katsanis E, Fuchs D, et al. Refractory pure red blood cell aplasia secondary to major ABO-incompatible allogeneic stem cell transplantation successfully treated with daratumumab. J Hematol. 2023;12:277\u201382. https:\/\/doi.org\/10.14740\/jh1195.","journal-title":"J Hematol"},{"key":"1315_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212007","volume":"14","author":"E Dovern","year":"2023","unstructured":"Dovern E, Biemond BJ, Nur E. Case report: successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease. Front Immunol. 2023;14:1212007. https:\/\/doi.org\/10.3389\/fimmu.2023.1212007.","journal-title":"Front Immunol"},{"key":"1315_CR21","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.12998\/wjcc.v12.i24.5604","volume":"12","author":"B Deng","year":"2024","unstructured":"Deng B, Gao R, Yang B, Lei WB, Xue MF, Wang JS, et al. Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: a case report and review of literature. World J Clin Cases. 2024;12:5604\u201312. https:\/\/doi.org\/10.12998\/wjcc.v12.i24.5604.","journal-title":"World J Clin Cases"},{"key":"1315_CR22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/trf.16281","volume":"61","author":"B Yates","year":"2021","unstructured":"Yates B, Molloy E, Dulau-Florea A, Braylan R, Hogan L, Hickstein DD, et al. Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation. Transfusion. 2021;61:1041\u20136. https:\/\/doi.org\/10.1111\/trf.16281.","journal-title":"Transfusion"},{"key":"1315_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000535927","volume":"51","author":"F Frioni","year":"2024","unstructured":"Frioni F, Metafuni E, Limongiello MA, Piccirillo N, Massini G, Pellegrino C, et al. Posttransplant autoimmune hemolytic anemia with anti-D specificity successfully treated with daratumumab: a case report. Transfus Med Hemother. 2024;51:355\u20138. https:\/\/doi.org\/10.1159\/000535927.","journal-title":"Transfus Med Hemother"},{"key":"1315_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/ejh.13343","volume":"104","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Alahmari A, Lipton JH. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol. 2020;104:145\u20137. https:\/\/doi.org\/10.1111\/ejh.13343.","journal-title":"Eur J Haematol"},{"key":"1315_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02479-w","author":"S Giammarco","year":"2024","unstructured":"Giammarco S, Limongiello MA, Di Marino L, Metafuni E, Teofili L, Chiusolo P, et al. The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA. Bone Marrow Transpl. 2024. https:\/\/doi.org\/10.1038\/s41409-024-02479-w.","journal-title":"Bone Marrow Transpl"},{"key":"1315_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/ejh.14341","volume":"114","author":"N Desai","year":"2025","unstructured":"Desai N, Viswabandya A, Kim DDH, Lipton JH, Mattsson J, Law AD. Daratumumab in the management of red cell aplasia following allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2025;114:310\u20134. https:\/\/doi.org\/10.1111\/ejh.14341.","journal-title":"Eur J Haematol"},{"key":"1315_CR27","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/s41409-020-0939-9","volume":"55","author":"A Gomez-Arteaga","year":"2020","unstructured":"Gomez-Arteaga A, Scordo M, Tamari R, Ruiz JD, Jakubowski AA, Papadopoulos EB, et al. Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series. Bone Marrow Transpl. 2020;55:2326\u201330. https:\/\/doi.org\/10.1038\/s41409-020-0939-9.","journal-title":"Bone Marrow Transpl"},{"key":"1315_CR28","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/j.1537-2995.2005.00578.x","volume":"45","author":"S Scholl","year":"2005","unstructured":"Scholl S, Klink A, Mugge LO, Schilling K, Hoffken K, Sayer HG. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Transfusion. 2005;45:1676\u201383. https:\/\/doi.org\/10.1111\/j.1537-2995.2005.00578.x.","journal-title":"Transfusion"},{"key":"1315_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1537-2995.2011.03295.x","volume":"52","author":"C Curley","year":"2012","unstructured":"Curley C, Pillai E, Mudie K, Western R, Hutchins C, Durrant S, et al. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange. Transfusion. 2012;52:291\u20137. https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03295.x.","journal-title":"Transfusion"},{"key":"1315_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5790011","volume":"2024","author":"M Nauffal","year":"2024","unstructured":"Nauffal M, Eng S, Lin A, Chan A, Mazzerella K, Giralt S, et al. Isatuximab for delayed red cell engraftment after allogeneic hematopoietic cell transplantation. Case Rep Hematol. 2024;2024:5790011 https:\/\/doi.org\/10.1155\/2024\/5790011.","journal-title":"Case Rep Hematol"},{"key":"1315_CR31","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41409-022-01590-0","volume":"57","author":"S Arslan","year":"2022","unstructured":"Arslan S, Ali H, Mei M, Marcucci G, Forman S, Nakamura R, et al. Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. Bone Marrow Transpl. 2022;57:830\u20133. https:\/\/doi.org\/10.1038\/s41409-022-01590-0.","journal-title":"Bone Marrow Transpl"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01315-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01315-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01315-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:35:59Z","timestamp":1749036959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01315-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01315-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}